⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Shanghai Huilun Pharmaceutical Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Shanghai Huilun Pharmaceutical Co., Ltd.
↗Shanghai, China
Shanghai Huilun Pharmaceutical Co., Ltd. (Huilun Pharma) is an innovative pharmaceutical enterprise based in Shanghai, China. The company operates an integrated system covering R&D, manufacturing, and commercialization, with a strategic focus on developing innovative drugs for major diseases and critical illnesses.
The company maintains a robust R&D infrastructure, including preclinical, pharmaceutical, and clinical research platforms. Their portfolio includes over 40 drug clinical trial approvals, more than 10 registered production approvals, and over 10 active pharmaceutical ingredient (API) approvals.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Innovative drug development
SIZE & FINANCIALS
Founded:2004
Ownership:private
Status:operating
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule
Active Trials:10
Trial Phases:Phase 1: 2 | Phase 2: 4 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd., Shanghai Huilun Life Science & Technology Co., Ltd.
COMPETITION
Position:Emerging
LINKS
Website:hllife.com.cn
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Shanghai Huilun Pharmaceutical Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.